RxDoctor Payments Data

Devon Briggs, MD

Psychiatry · Atlanta, GANPI 1649259714

Payments from drug & device makers

$2,056in general payments, 2019–2025

Across 80 payments — averaging $25.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$411
  • Johnson & Johnson$396
  • Otsuka America Pharmaceutical, Inc.$351
  • Lundbeck LLC$233
  • Indivior Inc.$220
  • Alkermes, Inc.$188
  • plus $256 from 5 others

What the payments were for

  • Food & beverage$2,050100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,056 in reported general payments places this provider in the 75th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$16,755
Medicare patients
34
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate92$290,035
AristadaAripiprazole Lauroxil13$26,921
Aripiprazole39$3,808
Divalproex Sodium ErDivalproex Sodium53$2,111
Olanzapine13$1,717
Fluphenazine Decanoate13$1,204
Topiramate85$1,089
Cyproheptadine Hcl17$858
Alprazolam135$749
Quetiapine Fumarate45$709
Zolpidem Tartrate129$633
Haloperidol20$554
Benztropine Mesylate49$538
Trazodone Hcl119$515
Fluoxetine Hcl48$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$396$290,03592 claims
Alkermes, Inc.Aristada$188$26,92113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →